Clinical and Molecular Hepatology

Papers
(The H4-Index of Clinical and Molecular Hepatology is 30. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-02-01 to 2025-02-01.)
ArticleCitations
Letter: cervicocerebral atherosclerosis and its hepatic and coronary risk factors in patients with liver cirrhosis307
Targeting TM4SF1 to overcome immunotherapy resistance in hepatocellular carcinoma205
Reply to correspondence on “Circulating cell-free mitochondrial DNA for diagnosing hepatocellular carcinoma and assessing prognosis”176
Antiviral therapy for chronic hepatitis B with mildly elevated aminotransferase: A rollover study from the TORCH-B trial161
Metabolic dysfunction-associated steatotic liver disease across women’s reproductive lifespan and issues160
Letter regarding “Prevalence of clinically significant liver fibrosis in the general population”116
Urgent need for education on hepatocellular carcinoma surveillance among high-risk population in China74
Identification of KCTD17 as a Ras stabilizer in hepatocellular carcinoma: Editorial on “KCTD17-mediated Ras stabilization promotes hepatocellular carcinoma progression”66
Correspondence to letter to the editor on “Transarterial radioembolization versus tyrosine kinase inhibitor in hepatocellular carcinoma with portal vein thrombosis”64
Correspondence to letter to the editor on “Bariatric intervention improves metabolic dysfunction-associated steatohepatitis in patients with obesity: A systematic review and meta-analysis”64
Correspondence to letter to the editor 2 on “Conventional and machine learning-based risk scores for patients with early-stage hepatocellular carcinoma”57
Reply to correspondence on “Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using vibration-controlled transient elastography: Systematic review and meta-analysis”56
Correspondence to editorial on “UBE2S promotes glycolysis in hepatocellular carcinoma by enhancing E3 enzyme-independent polyubiquitination of VHL”53
A complement to epigenetics in metabolic dysfunction-associated steatotic liver disease: Editorial on “DNA methylome analysis reveals epigenetic alteration of complement genes in advanced metabolic dy50
Comment: Non-invasive prediction of post-sustained virological response hepatocellular carcinoma in hepatitis C virus45
Correspondence to editorial 2 on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: insights from the IMbrave150 trial”44
Correspondence to editorial 1 on “Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: insights from the IMbrave150 Trial”44
Correspondence to editorial on “Prevalence of clinically significant liver fibrosis in the general population: A systematic review and meta-analysis”43
Correspondence to editorial on “Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using vibration-controlled transient elastography: Systematic review and meta-analysis42
Metabolic dysfunction-associated steatotic liver disease exhibits sex-specific microbial heterogeneity within intestinal compartments41
Unveiling the Intratumor Microbiome in Liver Cancer: Current Insights and Prospective Applications39
Hepatitis B core-related antigen dynamics and risk of subsequent clinical relapses after nucleos(t)ide analog cessation36
The rise of non-invasive tools in the diagnosis of portal hypertension: Validation of the Baveno VII consensus35
Non-invasive imaging biomarkers for liver steatosis in non-alcoholic fatty liver disease: present and future34
Cardiovascular risk of tenofovir disoproxil fumarate or tenofovir alafenamide in patients with chronic hepatitis B: More questions than an answer33
Both liver parenchymal and non-parenchymal cells express JCAD protein under various circumstances32
Correspondence on Letter regarding “Impacts of muscle mass dynamics on prognosis of outpatients with cirrhosis”32
Surveillance for hepatocellular carcinoma: It is time to move forward32
Optimizing off-treatment outcome predictions: The potential of time-varying HBcrAg and the need for more research32
Screening and prediction of nonalcoholic fatty liver disease using a peripheral insulin resistance index: Potential benefits and limitations31
Correspondence on Letter 1 regarding “Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma”30
0.038972854614258